Aurélie Jourdes, Elise Cellerin, Cyrille Touzeau, Stéphanie Harel, Blandine Denis, Guillaume Escure, Emmanuel Faure, Simon Jamard, Francois Danion, Cécile Sonntag, Florence Ader, Lionel Karlin, Sarah Soueges, Clarisse Cazelles, Clémentine de La Porte des Vaux, Laurent Frenzel, Fanny Lanternier, Xavier Brousse, Titouan Cazaubiel, Pierre Berger, Aude Collignon, Mathieu Blot, Andrea Pieragostini, Morgane Charles, Carine Chaleteix, Alexis Redor, Virginie Roland, Tom Cartau, Margaret Macro, Thomas Chalopin, Nicolas Vallet, Aurore Perrot, Guillaume Martin-Blondel
OBJECTIVES: Bispecific antibodies (BsAbs) are an effective treatment used in relapsed/refractory multiple myeloma. Despite a well-tolerated safety profile, infectious events appeared to be frequent in clinical trials. Real-world data on epidemiology, characteristics, risk factors and outcomes of infections in patients treated with BsAb are still needed. METHODS: A retrospective, multicenter study in BsAb-treated MM patients was conducted in 14 French centers from December 2020 to February 2023...
March 1, 2024: Clinical Microbiology and Infection